Ensysce Biosciences, Inc. (ENSC): Total Assets
$7.45M
As of 2025-12-31
$2.96M
As of 2026-06-30
+8.2%
3-year compound annual growth
+84.2%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $7.45M | +33.1% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $5.60M | +106.7% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $2.71M | -54.0% | 2025-03-10, Balance as of period end |
| 2022-12-31 | $5.89M | -64.2% | 2024-03-15, Balance as of period end |
| 2021-12-31 | $16.42M | n/m | 2023-03-30, Balance as of period end |
| 2020-12-31 | $351.8K | -99.8% | 2022-03-31, Balance as of period end |
| 2019-12-31 | $196.51M | -4.1% | 2021-06-08, Balance as of period end |
| 2018-12-31 | $204.83M | +1.2% | 2020-03-10, Balance as of period end |
| 2017-12-31 | $202.43M | n/a | 2019-03-12, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | $7.45M | +33.1% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $59.87M | -5.3% |
| China Pharma Holdings, Inc. (CPHI) | 2025-12-31 | $31.00M | +108.2% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $113.51M | -49.8% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $22.88M | -46.9% |
| Immunome Inc. (IMNM) | 2025-12-31 | $683.19M | +184.4% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $150.83M | +114.5% |
| Marker Therapeutics, Inc. (MRKR) | 2025-12-31 | $19.07M | -13.4% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $150.93M | +63.8% |
Compare ENSC, PRPH, CPHI, KRRO side by side · Screen every company in Pharmaceutical Preparations ↗